#USA #Houston #biotechnology #Decoy Therapeutics #DCOY

Decoy Therapeutics Issues Correction on Warrant Inducement

In a recent announcement, Decoy Therapeutics, Inc. (NASDAQ: DCOY) sought to clarify a mistake made in their previous press release dated September 22, 2026, concerning the Company’s warrant inducement transaction. This correction emphasizes the details regarding the issuance and exercisability of new unregistered warrants.

The initial press release mistakenly suggested that the new warrants, which allow the purchase of up to 2,368,868 shares of the Company’s common stock, would require approval from shareholders before they could be exercised. However, Decoy has now clarified that these new warrants will be exercisable immediately upon issuance, negating the need for any stockholder approval. Moreover, these warrants are set to expire five years from their issuance date. Aside from this, all other content from the original release remains unchanged.

About Decoy Therapeutics

Decoy Therapeutics has emerged as a pivotal player in the biotechnology sector with their innovative approach to antiviral drug development. Specializing in Designable Multi-Antivirals (D-MAVs), the company has engineered a new genre of antiviral treatments that aim to target shared mechanisms across various viruses. This pioneering technology is rooted in their proprietary IMP(3)ACT platform, which skillfully blends AI-assisted design with rapid synthesis methods. As a result, Decoy strives to expedite the entry of its peptide antiviral candidates into clinical contexts, thereby enhancing the scope of viral prevention and treatment.

The flagship candidates from Decoy Therapeutics are particularly geared towards countering multiple respiratory viruses, which reflects their broader commitment to tackling health challenges and minimizing the societal impact of viral diseases.

Forward-Looking Statements

As part of its communications, Decoy Therapeutics also issues forward-looking statements defined under the Private Securities Litigation Reform Act of 1995. These statements encompass the Company's anticipations regarding the attainment of milestones for its lead asset and its long-term prospects. They may express aspirations and strategies about future initiatives and results, which hinge upon current management beliefs and the assumptions that guide them.

It's vital to note that such statements often carry inherent risks and uncertainties. As indicated by the Company, actual results may diverge substantially from those anticipated due to various factors, such as the potential inadequacy of financing to fulfill business objectives or unforeseen complications in the drug development pipeline, including issues related to their IND applications and challenges with the performance of the IMP(3)ACT platform.

In light of these considerations, stakeholders and interested parties are encouraged to thoroughly review the disclosures made by Decoy Therapeutics in its filings with the SEC, particularly its Annual Report on Form 10-K for the fiscal year that concluded on December 31, 2025, along with subsequent filings. These documents will provide essential insights into potential risks and uncertainties that could influence the Company's future performance.

For inquiries, Decoy Therapeutics has made the following contacts available: Mark Rosenblum, CFO for investor relations, and Tara Mulloy from TMC Studio for media inquiries.

In conclusion, Decoy Therapeutics remains dedicated to improving healthcare outcomes through its innovative antiviral solutions, while also prioritizing transparency in communications concerning its progress and future ventures.